Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,174 across all filing types
Latest filing 2024-11-07 Investor Presentation
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Investor Presentation - Q2 FY25
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation Q2 FY25' and is addressed to stock exchanges with a subject line explicitly stating it is an investor presentation for the second quarter of fiscal year 2025. The content includes detailed financial metrics, business performance data, growth metrics, key developments, sales mix, market highlights, R&D and quality goals, and quarterly financial trends. It contains forward-looking statements and detailed operational and financial data typical of investor presentations. The document length is substantial (15,000 characters), indicating it is the full presentation rather than a brief announcement. There is no indication that this is a regulatory filing, earnings release summary, or annual/interim report. Therefore, the document fits the definition of an Investor Presentation (IP).
2024-11-07 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation Q2 FY25' and is addressed to stock exchanges with a subject line explicitly stating it is an investor presentation for the second quarter of fiscal year 2025. It contains detailed financial metrics, business performance data, growth metrics, key developments, sales mix, market performance, R&D updates, and other strategic information typically found in investor presentations. The document is about 15,000 characters long, which is consistent with a detailed presentation rather than a brief announcement. There is no indication that this is a full quarterly report with comprehensive financial statements, nor is it an earnings release with only key highlights. Instead, it is a detailed presentation aimed at investors, consistent with the definition of an Investor Presentation (IP).
2024-11-07 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated November 7, 2024, reporting unaudited financial results for the quarter and half year ended September 30, 2024. It includes detailed financial highlights such as sales, EBITDA, PBT, PAT, segment sales, and operational highlights. The document references Regulation 30 of SEBI Listing Regulations, which pertains to disclosure of material events including financial results. The content is comprehensive and contains actual financial data and analysis for the quarter, not just a brief announcement or a link to a report. It is not a full annual report but a quarterly financial disclosure. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2025
2024-11-07 English
Lupin Q2 FY2025 Results
Earnings Release Classification · 95% confidence The document is a press release dated November 7, 2024, reporting unaudited financial results for the quarter and half year ended September 30, 2024. It includes detailed financial highlights such as sales, EBITDA, PBT, PAT, segment sales, and operational highlights. The document explicitly states it is a press release and contains comprehensive financial data for Q2 FY2025. It is not a full annual report but a quarterly financial results announcement. The presence of unaudited quarterly financial results and detailed financial metrics aligns with the definition of an Earnings Release (ER). The document is over 11,000 characters, so it is not a mere announcement of a report but contains substantive financial data. Therefore, the correct classification is Earnings Release (ER). Q2 2025
2024-11-07 English
Financial Result Updates
Regulatory Filings
2024-11-07 English
Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2024.
Regulatory Filings
2024-11-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.